Digital Drug Discovery & Design

Tetra-d is the next-generation machine-intelligent platform powered by computer vision that enables fast, high-precision, and automated spatiotemporal analysis for computer-aided drug discovery.
Hard-to-drug
targets
Spatiotemporal modeling system considers the dynamic nature of molecules, exploring druggability of the most difficult pharmacological targets, such as protein complexes and RNA.
Chemical space
exploration
High-performance methods coupled with GPU-enhanced computations enable fast virtual screening of industry-level chemical libraries and protein optimization.
Target-specific machine intelligence
Our predictive models take into account peculiarities of your target enabling hit discovery, while minimizing false positive candidates that can squander resources.
Tetra-d boosts drug discovery with a proprietary state-of-the-art solutions to provide the full spectrum of functionality found in modern CADD
Target identification                                     
           Hit identification                                                   
                                                  lead optimization
Target druggability analysis
  • Allosteric
  • Oligomer-specific
  • Variant-specific
Virtual Ligand Screening
  • AI-based chemical space exploration
  • AI-based physicochemical property profiling
  • AI-based ADMET property profiling
Ligand-based Drug Discovery
  • AI-based QSAR models
  • AI-based synthetic accessibility profiling
  • AI-based de-novo drug design
Structure-based Drug Design
  • AI-based molecular docking
  • AI-based selectivity and off-target profiling
  • AI-based poly-pharmacological profiling
Under the hood
Machine intelligent analysis of  molecular “movies” that captures molecular structures evolving over time.
Ultrarapid validation algorithms are magnitudes faster than the key available commercial solutions.
High-precision binding profiling of proteins, protein oligomers, RNA, or protein-RNA complexes.
Solution versatility that permits working with a broad range of therapeutic entities, including small molecules, peptides, covalent molecules, or macrolides.
Speed
Conformations per minute
Tetra-D
Fpocket
deepsite
sitemap
5,000x
faster than the leading commercial solutions
2.5x
more true positives than by leading solutions
4x
less false positives than by leading solutions
Tetra-D team has published 30+ peer-reviewed scientific papers
“Spatiotemporal identification of druggable binding sites using deep learning”
Communications Biology, 2020
“5-HT2C receptor structures reveal the structural basis of GPCR polypharmacology”
Cell, 2018
“Computational design of thermostabilizing point mutations for G protein-coupled receptors”
eLife, 2018
“Crystal structure of the Frizzled 4 receptor in a ligand-free state”
Nature, 2018
“Structure-based seed learning for binding site detection in nucleic acid macromolecules”
NAR Genomics and Bioinformatics, 2021
“Structural insights on ligand recognition at the human leukotriene B4 receptor 1”
Nature communications, 2021
“graphDelta: MPNN Scoring Function for the Affinity Prediction of Protein-Ligand Complexes”
ACS Omega, 2020
“Crystal structure of the human cannabinoid receptor CB2”
Cell, 2019
“Protein-Peptide Binding Site Detection using 3D Convolutional Neural Networks”
Journal of Chemical Information and Modelling, 2021
“Structural basis for receptor selectivity and inverse agonism in S1P5 receptors“
Nature communications, 2022
cadd Innovation from switzerland
Tetra-D was established in 2022 in Schaffhausen, Switzerland with R&D center in Bremen, Germany aiming to expand the druggable genome by enabling drug discovery for hard-to-drug pharmaceutical targets. Our team has more than 10-year experience in the spatiotemporal analysis of molecules powered by machine learning and molecular modeling. Dr. Petr Popov and Dr. Serg Bell co-founded the company. Dr. Popov is an expert in machine learning applied to structural biology and co-authored 30+ articles in top-tier journals. And Dr. Bell is a seasoned technology entrepreneur and investor.
Dr. Serg Bell
Co-founder
Dr. Petr Popov
Co-founder
Ezequiel Steiner
Co-founder
30+
articles
in top-tier journals
10+
years
of experience in the spatiotemporal analysis
5
team members
versed in biophysics and AI/ML applications to molecule dynamics
Contact Us
Tetra-d is starting to partner with leading pharma and biotechnology companies and academia to demonstrate our capabilities. Please contact us to discuss your challenging project. We are interested to hear about protein, RNA or small molecule drug discovery programs, as well as protein design!
By providing your email address, you agree to receive an email response from Tetra-D to your inquiry. Your email address will only be used to respond to your inquiry. The information you submit will be governed by our Privacy Policy.
Your message has been sent successfully. We will contact you.
The message was not sent. Check if the fields are filled in correctly.
Copyright 2023 Tetra-D
All Rights Reserved